Where does Generate Biomedicines, Inc. 's cash flow data come from?

Every line is extracted from Generate Biomedicines, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26
Net income	-$61.71M-39.3%
Depreciation and amortization	$3.27M-4.1%
Stock-based compensation	$6.4M+34.8%
Change in accounts receivable	$0-100%
Change in accounts payable	$3.75M+729%
Change in accrued liabilities	-$21.05M-229%
Net cash from operating activities	-$80.39M-51.2%
Capital expenditures	$3.78M+403%
Net cash from investing activities	-$259.93M-444%
Proceeds from issuance of common stock	$3.22M+566%
Net cash from financing activities	$378.89M+1,743%
Net increase (decrease) in cash	$38.57M-10.1%
Deferred revenue	-$7.22M+18.1%
Operating lease liabilities	-$1.84M-3,247%
Other long-term liabilities	-$117K0.0%
Increase (Decrease) in Other Operating Assets	-$2.05M-46.1%
Increase (Decrease) in Prepaid Expense and Other Assets	$6.22M+126%
Finance Lease, Principal Payments	$1.12M-57.9%
Net proceeds from sales of subsidiary shares	$369.29M—
Proceeds From Issuance Of Convertible Preferred Stock	$0-100%
Accrued payables for capital expenditures	$25K-57.6%
Increase Decrease In Operating Lease Liability	-$1.84M-3,247%
Conversion Of Convertible Preferred Stock To Common Stock	$811.83M—
Reclassification Of Warrant Liability To Equity Upon Initial Public Offering	$1.57M—
Vesting Of Restricted Stock	$0-100%
Free cash flow	-$84.17M-56.1%
Free cash flow	-$84.17M-56.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Generate Biomedicines, Inc. 's cash flow data come from?: Every line is extracted from Generate Biomedicines, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.